Mesenchymal stem cells (MSCs) are one of a few stem cell types to be applied in clinical
practice as therapeutic agents for immunomodulation and ischemic tissue repair. In addition …

Myocardial infarction (MI) is one of the leading causes of mortality worldwide and is
associated with irreversible cardiomyocyte death and pathological remodeling of cardiac …

Intratracheal transplantation of human umbilical cord blood (UCB)–derived mesenchymal
stem cells (MSCs) protects against neonatal hyperoxic lung injury by a paracrine rather than …

Mesenchymal stromal cells (MSCs) are promising candidates for cell therapy. Their
therapeutic use requires extensive expansion to obtain a sufficiently high number of cells for …

Background Ischemia-reperfusion injury (IRI) of the liver is a well-known cause of morbidity
and mortality after liver transplantation. Effective treatment strategies aimed at decreasing …

Progressive fibrosis is a pathological hallmark of many chronic diseases responsible for
organ failure. Although there is currently no therapy on the market that specifically targets …

Remote ischemic preconditioning (RIPC), the repetitive transient mechanical obstruction of
vessels at a limb remote to the operative site, is a novel strategy to mitigate distant organ …

Purpose: Liver injury triggered by intestinal ischemia-reperfusion (IIR) usually presage
multiorgan dysfunction and death in patients. Recent studies suggest mesenchymal stem …

Diphosphoinositol pentakisphosphate (IP7), formed by a family of inositol hexakisphosphate
kinases (IP6Ks), has been demonstrated to be a physiologic inhibitor of Akt. IP6K inhibition …

Objective To evaluate the impact of mesenchymal stem cells (MSCs) against hepatic I/R
injury and explore the role of N-acetyltransferase 8 (NAT8) in the process. Methods We …